{
    "pmcid": "11405125",
    "qa_pairs": {
        "How does IsAb2.0 improve upon its predecessor, IsAb1.0, in terms of design capabilities?": [
            "It supports nanobody and humanized antibody design without requiring homologous structures.",
            "It uses X-ray crystallography to validate antibody designs.",
            "It requires less computational power to predict antibody structures.",
            "It focuses solely on designing antibodies for bacterial infections."
        ],
        "What future improvement is mentioned for the IsAb2.0 protocol?": [
            "Addressing limitations in point mutation accuracy and automating the process.",
            "Incorporating real-time data from clinical trials.",
            "Developing a mobile app for antibody design.",
            "Integrating quantum computing for faster predictions."
        ],
        "What is the primary advantage of using AlphaFold-Multimer in IsAb2.0 for antibody design?": [
            "It eliminates the need for homologous templates and pre-existing binding information.",
            "It significantly reduces the cost of antibody production.",
            "It allows for the design of antibodies without any computational resources.",
            "It provides a direct method for synthesizing antibodies in the lab."
        ],
        "What specific feature of nanobodies makes them suitable for targeting viral proteins like the SARS-CoV-2 spike protein?": [
            "Their small size and stability allow for deep tissue penetration.",
            "Their ability to bind to multiple antigens simultaneously.",
            "Their resistance to degradation in the bloodstream.",
            "Their capacity to be easily modified with fluorescent tags."
        ],
        "Which mutation was confirmed to enhance binding affinity in the HuJ3-gp120 complex validation?": [
            "E44R",
            "K58N",
            "D32A",
            "L76F"
        ]
    }
}